← Back to Search

Digital Diabetes Prevention Program with Automated Messaging for Prediabetes

N/A

Waitlist Available

Led By Devin Mann, MD

Research Sponsored by NYU Langone Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

A diagnosis of prediabetes (either diagnosis of prediabetes or an HbA1C level of 5.7%-6.4% in past 12 months) or diabetes risk factors (BMI ≥ 25 kg/m2 or > 22 kg/m2 if self-identified as Asian

18 years or older, BMI ≥ 25 kg/m2 (> 22 kg/m2 if self-identified as Asian)

Must not have

Diagnosed with diabetes

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through completion of ddpp program (average 1 year)

Awards & highlights

No Placebo-Only Group

Summary

This trial looks at whether sending automated, tailored messages to patients enrolled in a digital diabetes prevention program can help increase engagement and prevent the onset of diabetes.

Who is the study for?

This trial is for NYU Langone patients over 18 with a BMI ≥ 25 (or > 22 if Asian), who can safely exercise, speak English well enough to enroll, have an app-capable device, and are diagnosed with prediabetes or at risk of diabetes. It excludes those already diagnosed with diabetes, unable to exercise moderately due to health conditions, significant weight fluctuation issues unrelated to the intervention, or severe psychiatric disease/dementia.

What is being tested?

The study tests whether automated messages from doctors can increase patient involvement in a digital diabetes prevention program. The messages vary based on how much patients use the dDPP app and aim to prevent diabetes onset and improve outcomes by encouraging more engagement through texts and MyChart messages.

What are the potential side effects?

Since this trial involves digital messaging rather than medication or medical procedures, traditional side effects are not expected. However, participants may experience increased screen time which could lead to eye strain or disrupted sleep patterns if using devices before bedtime.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have prediabetes or am at risk for diabetes due to my weight.

Select...

I am over 18 and have a BMI of 25 or higher (22 if I'm Asian).

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have been diagnosed with diabetes.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through completion of ddpp program (average 1 year)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through completion of ddpp program (average 1 year)

This trial's timeline: 3 weeks for screening, Varies for treatment, and through completion of ddpp program (average 1 year) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Body Mass Index (BMI) (kg/m2)

Body Weight (kilograms)

Hemoglobin A1c (HbA1c) level (mmol/mol)

Secondary study objectives

dDPP platform coach messages sent

dDPP platform exercise log (min)

dDPP platform group social posts sent

+4 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Experimental groupExperimental Treatment2 Interventions

Participants will be enrolled virtually into a digital diabetes prevention program through the Noom app and willing to receive text messages based on their engagement levels in Noom from the study team, as well as complete text-based surveys.

Group II: Control groupExperimental Treatment1 Intervention

Participants will be enrolled virtually into the digital diabetes prevention program through the Noom app and willing to receive general text messages from the study team

0 / 3Eligibility criteria met